Artículos de revistas sobre el tema "BCR-ABL like"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "BCR-ABL like".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Gross, Alec W., Xiaowu Zhang y Ruibao Ren. "Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy". Molecular and Cellular Biology 19, n.º 10 (1 de octubre de 1999): 6918–28. http://dx.doi.org/10.1128/mcb.19.10.6918.
Texto completoCross, Nick. "BCR-ABL Negative CML-Like Disorder". Clinical Lymphoma Myeloma and Leukemia 17 (septiembre de 2017): S107—S108. http://dx.doi.org/10.1016/j.clml.2017.08.052.
Texto completoHe, Yiping, Jason A. Wertheim, Lanwei Xu, Juli P. Miller, Fredrick G. Karnell, John K. Choi, Ruibao Ren y Warren S. Pear. "The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia–like disease by bcr/abl". Blood 99, n.º 8 (15 de abril de 2002): 2957–68. http://dx.doi.org/10.1182/blood.v99.8.2957.
Texto completoHao, Sheryl X. y Ruibao Ren. "Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder". Molecular and Cellular Biology 20, n.º 4 (15 de febrero de 2000): 1149–61. http://dx.doi.org/10.1128/mcb.20.4.1149-1161.2000.
Texto completoZheng, Xiaomin, Saskia Güller, Gesine Bug, Bithia Grace, Roxana Bistrian, Dieter Hoelzer, Oliver G. Ottmann, Reinhard Henschler y Martin Ruthardt. "The Reciprocal t(9;22)-Translocation Products ABL/BCR Have Leukemogenic Potential Independently from BCR/ABL." Blood 104, n.º 11 (16 de noviembre de 2004): 214. http://dx.doi.org/10.1182/blood.v104.11.214.214.
Texto completoMillion, Ryan P. y Richard A. Van Etten. "The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase". Blood 96, n.º 2 (15 de julio de 2000): 664–70. http://dx.doi.org/10.1182/blood.v96.2.664.014k52_664_670.
Texto completoMillion, Ryan P. y Richard A. Van Etten. "The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase". Blood 96, n.º 2 (15 de julio de 2000): 664–70. http://dx.doi.org/10.1182/blood.v96.2.664.
Texto completoAlbers, Corinna, Anna L. Illert, Cornelius Miething, Christian Peschel y Justus Duyster. "Grb10 Mediated Akt Activation Is Required for Induction of CML Like Myeloproliferative Disease in Mice by BCR-ABL." Blood 110, n.º 11 (16 de noviembre de 2007): 1012. http://dx.doi.org/10.1182/blood.v110.11.1012.1012.
Texto completoMohi, M. Golam, Wayne W. Chan, Shaoguang Li, Benjamin Neel y Richard A. Van Etten. "Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL". Blood 112, n.º 11 (16 de noviembre de 2008): 570. http://dx.doi.org/10.1182/blood.v112.11.570.570.
Texto completoAlbers, Corinna, Anna Lena Illert, Cornelius Miething, Christian Peschel y Justus Duyster. "Raf1 Is Required for Induction of a Bcr-Abl Positive CML Like Myeloproliferative Disease in Mice". Blood 112, n.º 11 (16 de noviembre de 2008): 3207. http://dx.doi.org/10.1182/blood.v112.11.3207.3207.
Texto completoPelletier, Shawn D., Daniel S. Hong, Yiguo Hu, Yuhua Liu y Shaoguang Li. "Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice". Blood 104, n.º 7 (1 de octubre de 2004): 2163–71. http://dx.doi.org/10.1182/blood-2003-09-3033.
Texto completoFredericks, Jessica, Chaitali Parikh, Ramesh Subrahmanyam y Ruibao Ren. "The RALGEF Pathway Contributes to the Pathogenesis of Chronic Myelogenous Leukemia by BCR/ABL". Blood 112, n.º 11 (16 de noviembre de 2008): 3208. http://dx.doi.org/10.1182/blood.v112.11.3208.3208.
Texto completoMillion, Ryan P., Jon Aster, D. Gary Gilliland y Richard A. Van Etten. "The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice". Blood 99, n.º 12 (15 de junio de 2002): 4568–77. http://dx.doi.org/10.1182/blood-2001-12-0244.
Texto completoMian, Afsar, Isabella Haberbosch, Oliver G. Ottmann y Martin Ruthardt. "Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL". Blood 124, n.º 21 (6 de diciembre de 2014): 4523. http://dx.doi.org/10.1182/blood.v124.21.4523.4523.
Texto completoMinami, Yosuke, Scott Stuart, Tomokatsu Ikawa, Asoka Banno, Irina Hunton, Karl Willert, Cornelis Murre, Catriona Jamieson y Jean Y. J. Wang. "Imatinib-Resistant Activation of β-Catenin by BCR-ABL in a Murine Model of Chronic Myelogenous Leukemia Stem Cells." Blood 108, n.º 11 (1 de noviembre de 2006): 2126. http://dx.doi.org/10.1182/blood.v108.11.2126.2126.
Texto completoZafar, Usva, Mohammed Yusuf, Rikhia Chakraborty, El-Nasir M. A. Lalani y Afsar Ali Mian. "The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia". Blood 134, Supplement_1 (13 de noviembre de 2019): 5196. http://dx.doi.org/10.1182/blood-2019-131694.
Texto completoHantschel, Oliver D., Eva Eckelhart, Ines Kaupe, Florian Grebien, Kay-Uwe Wagner, Veronika Sexl y Giulio Superti-Furga. "Bcr-Abl Directly Activates Stat5 Independent of Jak2". Blood 116, n.º 21 (19 de noviembre de 2010): 511. http://dx.doi.org/10.1182/blood.v116.21.511.511.
Texto completoCrawford, Lisa, Philip Windrum, Laura Magill, Junia V. Melo, Lynn McCallum, MaryFrances McMullin, Huib Ovaa, Brian Walker y Alexandra Irvine. "Bcr-Abl Positive Cells Display Increased Proteasome Activity and Greater Sensitivity to Proteasome Inhibition". Blood 112, n.º 11 (16 de noviembre de 2008): 3192. http://dx.doi.org/10.1182/blood.v112.11.3192.3192.
Texto completoSha, Xiaojin, Dan Liebermann y Barbara Hoffman. "Loss of Gadd45b Accelerates BCR-ABL-Driven CML". Blood 132, Supplement 1 (29 de noviembre de 2018): 5138. http://dx.doi.org/10.1182/blood-2018-99-114890.
Texto completoZhang, Bin, Yin Wei Ho, Sung-UK Lee, Takahiro Maeda, Claudia Huettner y Ravi Bhatia. "Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML)." Blood 114, n.º 22 (20 de noviembre de 2009): 858. http://dx.doi.org/10.1182/blood.v114.22.858.858.
Texto completoHantschel, Oliver D., Florian Grebien, Ines Kaupe, Boris Kovacic, John Wojcik, Gerald D. Gish, Shohei Koide, Hartmut Beug, Tony Pawson y Giulio Superti-Furga. "The Bcr-Abl SH2-Kinase Domain Interface Is Critical for Leukemogenesis and An Additional Therapeutic Target in CML." Blood 114, n.º 22 (20 de noviembre de 2009): 37. http://dx.doi.org/10.1182/blood.v114.22.37.37.
Texto completoMoore, James C., Chi Ly, Halbur Luke y S. Tiong Ong. "Enhanced Killing of Chronic Myelogenous Leukemia Cells by Rapamycin and Imatinib Is Associated with Differential Inhibition of 4E-BP1 and eIF4E Phosphorylation and Decreased Protein Expression by Non-Overlapping Mechanisms." Blood 104, n.º 11 (16 de noviembre de 2004): 1993. http://dx.doi.org/10.1182/blood.v104.11.1993.1993.
Texto completoBurgess, Gem S., Elizabeth A. Williamson, Larry D. Cripe, Sara Litz-Jackson, Jay A. Bhatt, Kurt Stanley, Mark J. Stewart, Andrew S. Kraft, Harikrishna Nakshatri y H. Scott Boswell. "Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase". Blood 92, n.º 7 (1 de octubre de 1998): 2450–60. http://dx.doi.org/10.1182/blood.v92.7.2450.
Texto completoBurgess, Gem S., Elizabeth A. Williamson, Larry D. Cripe, Sara Litz-Jackson, Jay A. Bhatt, Kurt Stanley, Mark J. Stewart, Andrew S. Kraft, Harikrishna Nakshatri y H. Scott Boswell. "Regulation of the c-jun Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-jun N-Terminal Kinase". Blood 92, n.º 7 (1 de octubre de 1998): 2450–60. http://dx.doi.org/10.1182/blood.v92.7.2450.2450_2450_2460.
Texto completoPear, Warren S., Juli P. Miller, Lanwei Xu, John C. Pui, Benny Soffer, Robert C. Quackenbush, Ann Marie Pendergast et al. "Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow". Blood 92, n.º 10 (15 de noviembre de 1998): 3780–92. http://dx.doi.org/10.1182/blood.v92.10.3780.
Texto completoPear, Warren S., Juli P. Miller, Lanwei Xu, John C. Pui, Benny Soffer, Robert C. Quackenbush, Ann Marie Pendergast et al. "Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow". Blood 92, n.º 10 (15 de noviembre de 1998): 3780–92. http://dx.doi.org/10.1182/blood.v92.10.3780.422k15_3780_3792.
Texto completoIllert, Anna Lena, Cornelius Miething, Rebekka Grundler, Manuel Schmidt, Andreas Burchert, Andreas Neubauer, Claudia Mugler, Christian Peschel y Justus Duyster. "Interferon Regulatory Factor 4 Is Not Required for Induction of Chronic Myeloid Leukaemia-Like Myeloproliferative Disease by Bcr/Abl in Mice." Blood 106, n.º 11 (16 de noviembre de 2005): 2866. http://dx.doi.org/10.1182/blood.v106.11.2866.2866.
Texto completoZhao, Xingwang, Hengyi Xie, Meng Zhao, Asma Ahsan, Xinxin Li, Fei Wang, Junyang Yi et al. "Fc receptor–like 1 intrinsically recruits c-Abl to enhance B cell activation and function". Science Advances 5, n.º 7 (julio de 2019): eaaw0315. http://dx.doi.org/10.1126/sciadv.aaw0315.
Texto completoLi, Shaoguang, Robert L. Ilaria, Ryan P. Million, George Q. Daley y Richard A. Van Etten. "The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity". Journal of Experimental Medicine 189, n.º 9 (3 de mayo de 1999): 1399–412. http://dx.doi.org/10.1084/jem.189.9.1399.
Texto completoKrause, Daniela S., Ulrich H. von Andrian y Richard A. Van Etten. "Selectins and Their Ligands Are Required for Homing and Engraftment of BCR-ABL+ Leukemia-Initiating Cells." Blood 106, n.º 11 (16 de noviembre de 2005): 697. http://dx.doi.org/10.1182/blood.v106.11.697.697.
Texto completole Coutre, Philipp, Elena Tassi, Marileila Varella-Garcia, Rossella Barni, Luca Mologni, Gonçalo Cabrita, Edoardo Marchesi, Rosanna Supino y Carlo Gambacorti-Passerini. "Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification". Blood 95, n.º 5 (1 de marzo de 2000): 1758–66. http://dx.doi.org/10.1182/blood.v95.5.1758.005a41_1758_1766.
Texto completoMian, Afsar, Anahita Rafiei, Claudia Oancea, Oliver G. Ottmann y Martin Ruthardt. "The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia". Blood 124, n.º 21 (6 de diciembre de 2014): 2402. http://dx.doi.org/10.1182/blood.v124.21.2402.2402.
Texto completoDemirel, Özlem, Olivier Balló, Hubert Serve y Christian H. Brandts. "The Role Of SOCS1 In BCR-ABL Mediated Transformation and Leukemogenesis". Blood 122, n.º 21 (15 de noviembre de 2013): 2507. http://dx.doi.org/10.1182/blood.v122.21.2507.2507.
Texto completoSha, Xiaojin, Dan A. Liebermann y Barbara Hoffman. "Loss of Growth Arrest DNA Damage 45a,b (GADD45a,b) Enhances Oncogenicity in BCR/ABL-Driven Chronic Myelogenous Leukemia." Blood 114, n.º 22 (20 de noviembre de 2009): 3264. http://dx.doi.org/10.1182/blood.v114.22.3264.3264.
Texto completoSlupianek, Artur, Stanislaw Jozwiakowski, Ewa Gurdek, Michal O. Nowicki y Tomasz Skorski. "BCR/ABL Regulates the Expression and Interacts with Werner Syndrome Helicase/Exonuclease To Modulate Its Biochemical Properties." Blood 106, n.º 11 (16 de noviembre de 2005): 2873. http://dx.doi.org/10.1182/blood.v106.11.2873.2873.
Texto completoEiring, Anna M., Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Ji Suk Chang, Carlo Gambacorti-Passerini, Stefano Volinia et al. "Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis." Blood 110, n.º 11 (16 de noviembre de 2007): 33. http://dx.doi.org/10.1182/blood.v110.11.33.33.
Texto completoCuiffo, Benjamin y Ruibao Ren. "Dominant Negative Effect of Palmitoylation-Deficient NRAS In Suppression of BCR/ABL Leukemogenesis". Blood 116, n.º 21 (19 de noviembre de 2010): 3157. http://dx.doi.org/10.1182/blood.v116.21.3157.3157.
Texto completoKrause, Daniela S., Katherine Lazarides, Ulrich H. von Andrian y Richard A. Van Etten. "CD44 Is Selectively Required for the Homing and Engraftment of BCR-ABL-Expressing Leukemic Stem Cells." Blood 108, n.º 11 (16 de noviembre de 2006): 743. http://dx.doi.org/10.1182/blood.v108.11.743.743.
Texto completoHsieh, Mo-Ying y Richard A. Van Etten. "Distinct Roles for the NF-κB Pathway In Myeloid and Lymphoid Transformation and Leukemogenesis by BCR-ABL." Blood 116, n.º 21 (19 de noviembre de 2010): 1225. http://dx.doi.org/10.1182/blood.v116.21.1225.1225.
Texto completoYu, Chuanjiang, Sivahari Prasad Gorantla, Tony Mueller, Lena Lippert, Zhenyu Yue, Robert Zeiser, Tobias Huber, Justus Duyster y Anna Lena Illert. "Beclin-1 Phosphorylation By BCR-ABL Is Crucial for CML Leukemogenesis By Suppression of Autophagy". Blood 126, n.º 23 (3 de diciembre de 2015): 16. http://dx.doi.org/10.1182/blood.v126.23.16.16.
Texto completoYamamoto, Kiyoko, Shinobu Tsuzuki, Tomoki Naoe y Masao Seto. "Deregulated Activity of AML1/RUNX1 Cooperates with BCR-ABL to Immortalize Hematopoietic Progenitor Cells and Induces Blast Crisis-Like Disease of Chronic Myelogenous Leukemia in Mice",. Blood 118, n.º 21 (18 de noviembre de 2011): 3749. http://dx.doi.org/10.1182/blood.v118.21.3749.3749.
Texto completoNardi, Valentina, Olaia Naveiras, Mohammad Azam y George Q. Daley. "A Critical Role for CCL Chemokines in the Immuno-Protection Induced by Type I Interferons and IRF8/ICSBP Against Bcr/Abl-Induced Leukemia." Blood 110, n.º 11 (16 de noviembre de 2007): 1001. http://dx.doi.org/10.1182/blood.v110.11.1001.1001.
Texto completoSanchez-Aguilera, Abel, Ami tava Sengupta, Joseph P. Mastin, Kyung H. Chang, David A. Williams y Jose A. Cancelas. "Rac2 GTPase Activation Is Necessary for Development of p190-BCR-ABL-Induced B-Cell Acute Lymphoblastic Leukemia". Blood 112, n.º 11 (16 de noviembre de 2008): 3790. http://dx.doi.org/10.1182/blood.v112.11.3790.3790.
Texto completoUchida, Naoya, Hideki Hanawa, Koiti Inokuchi, Kazuo Dan y Takashi Shimada. "Leukemogenesis of the b2a2 Type p210 BCR/ABL in a Bone Marrow Transplantation Mouse Model Using a Lentivirus Vector." Blood 106, n.º 11 (16 de noviembre de 2005): 2875. http://dx.doi.org/10.1182/blood.v106.11.2875.2875.
Texto completoChen, Ying, Nicole Froehlich y Stefan K. Bohlander. "Towards the In Vivo Identificaton of Leukemogenic Fusion Proteins." Blood 104, n.º 11 (16 de noviembre de 2004): 2970. http://dx.doi.org/10.1182/blood.v104.11.2970.2970.
Texto completoPeng, Cong, Julia Brain, Yiguo Hu, Linghong Kong, David Grayzel, Roger Pak, Margaret Read y Shaoguang Li. "IPI-504, a Novel, Orally Active HSP90 Inhibitor, Prolongs Survival of Mice with BCR-ABL T315I CML and B-ALL." Blood 108, n.º 11 (1 de noviembre de 2006): 2183. http://dx.doi.org/10.1182/blood.v108.11.2183.2183.
Texto completoGabert, Jean A., Christophe Picard, Sandrine Hayette, Christelle Bilhou-Nabera, Jean-Michel Cayuela, Elizabeth Macintyre, Nicole Frenoy et al. "Prospective Multicentric Molecular Study for Poor Prognosis Fusion Transcripts at Diagnosis in Adult ALL Patients - The LALA94 Experience." Blood 106, n.º 11 (16 de noviembre de 2005): 4476. http://dx.doi.org/10.1182/blood.v106.11.4476.4476.
Texto completoSingh, Aditya y Prateek Bhatia. "Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-Cas13a". Current Gene Therapy 21, n.º 3 (8 de junio de 2021): 270–77. http://dx.doi.org/10.2174/1566523221666210217155233.
Texto completoMinami, Yosuke, Scott A. Stuart, Tomokatsu Ikawa, Akihiro Abe, Tomoki Naoe, Catriona H. M. Jamieson y Jean Y. J. Wang. "Transformation of E2A-Deficient Pluripotent Progenitors by BCR-ABL Generates Imatinib-Resistant Leukemic Stem Cells." Blood 112, n.º 11 (16 de noviembre de 2008): 1342. http://dx.doi.org/10.1182/blood.v112.11.1342.1342.
Texto completoGleixner, Karoline V., Harald Herrmann, Barbara Peter, Katharina Blatt, Karina Schuch, Winfried F. Pickl, Christian Sillaber y Peter Valent. "The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition." Blood 116, n.º 21 (19 de noviembre de 2010): 3394. http://dx.doi.org/10.1182/blood.v116.21.3394.3394.
Texto completo